Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
IOVA 
Iovance Biotherapeutics Inc (IOVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: IOVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.35
1 Year Target Price $8.35
| 5 | Strong Buy |
| 3 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.15% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.04B USD | Price to earnings Ratio - | 1Y Target Price 8.35 |
Price to earnings Ratio - | 1Y Target Price 8.35 | ||
Volume (30-day avg) 12 | Beta 0.77 | 52 Weeks Range 1.64 - 6.50 | Updated Date 01/9/2026 |
52 Weeks Range 1.64 - 6.50 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -158.78% | Operating Margin (TTM) -133.06% |
Management Effectiveness
Return on Assets (TTM) -27.12% | Return on Equity (TTM) -53.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 787777401 | Price to Sales(TTM) 4.14 |
Enterprise Value 787777401 | Price to Sales(TTM) 4.14 | ||
Enterprise Value to Revenue 3.15 | Enterprise Value to EBITDA -8.68 | Shares Outstanding 396967970 | Shares Floating 338653375 |
Shares Outstanding 396967970 | Shares Floating 338653375 | ||
Percent Insiders 0.32 | Percent Institutions 61.8 |
Upturn AI SWOT
Iovance Biotherapeutics Inc
Company Overview
History and Background
Iovance Biotherapeutics, Inc. (formerly Lion Biologics and formerly Ligo Cyto Therapeutics) was founded in 2007. It is a biotechnology company focused on the development and commercialization of T cell immunotherapies. A significant milestone was the rebranding to Iovance Biotherapeutics in 2017, reflecting its focus on its lead product candidate, lifileucel. The company has been dedicated to advancing cancer treatment through the development of novel cellular therapies.
Core Business Areas
- Cellular Immunotherapy Development: Iovance's core business revolves around the research, development, and potential commercialization of T cell immunotherapies for various cancers. Their primary focus is on tumor-infiltrating lymphocyte (TIL) therapy.
- Clinical Trials and Regulatory Affairs: A significant part of their operation involves conducting extensive clinical trials to evaluate the safety and efficacy of their therapies, and navigating the complex regulatory approval processes with agencies like the FDA.
Leadership and Structure
Iovance Biotherapeutics is led by a management team with expertise in biotechnology, oncology, and drug development. The organizational structure is typical for a clinical-stage biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Product Name 1: [object Object]
- Product Name 2: [object Object]
Market Dynamics
Industry Overview
The oncology market, particularly the field of immunotherapy and cellular therapies, is experiencing rapid growth and innovation. There is a significant unmet medical need for more effective and durable treatments for various cancers, driving investment and research in novel therapeutic approaches.
Positioning
Iovance is positioned as a pioneer in TIL therapy, aiming to provide a novel, personalized approach to cancer treatment. Their competitive advantage lies in their unique TIL platform and their focus on delivering a potentially one-time, curative therapy. However, they face competition from established therapies and other emerging cell therapy companies.
Total Addressable Market (TAM)
The TAM for advanced melanoma and other solid tumors targeted by Iovance's therapies is substantial, estimated in the billions of dollars globally. Iovance is positioned to capture a significant portion of this market with its innovative TIL platform, especially as it gains regulatory approvals and expands its therapeutic applications.
Upturn SWOT Analysis
Strengths
- Proprietary TIL platform technology
- Breakthrough Therapy designation for lead product
- Experienced leadership team
- Focus on a personalized, potentially one-time treatment approach
Weaknesses
- Late-stage clinical development and regulatory hurdles
- Manufacturing complexity and scalability of TIL therapy
- High cost of development and potential treatment cost
- Limited commercialization experience for a novel therapy
Opportunities
- Expanding TIL therapy to other solid tumors
- Strategic partnerships and collaborations
- Advancements in manufacturing and logistics for cell therapies
- Increasing demand for personalized medicine
Threats
- Failure to achieve regulatory approval
- Competition from existing and emerging therapies
- Adverse clinical trial results
- Reimbursement challenges for novel therapies
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- Merck & Co., Inc. (MRK)
- Bristol Myers Squibb Company (BMY)
- Moderna, Inc. (MRNA)
Competitive Landscape
Iovance's competitive landscape is dynamic and includes large pharmaceutical companies with established oncology portfolios and significant R&D budgets, as well as other innovative biotechnology companies developing novel cell therapies. Iovance's advantage lies in its differentiated TIL platform for solid tumors, while its disadvantages include its smaller size, reliance on a few key assets, and the inherent risks of drug development.
Growth Trajectory and Initiatives
Historical Growth: Iovance's historical growth has been characterized by significant investment in its scientific platform and clinical pipeline, leading to the advancement of its lead product candidate through clinical trials. This growth has been primarily fueled by capital raises.
Future Projections: Future projections are heavily dependent on the successful commercialization of Amtagvi and the advancement of its pipeline into other indications. Analyst estimates generally anticipate significant revenue growth post-approval, but also continued substantial R&D investment.
Recent Initiatives: Recent initiatives include the ongoing commercial launch of Amtagvi for advanced melanoma, continued clinical development across various solid tumors, and efforts to enhance manufacturing capabilities and partnerships.
Summary
Iovance Biotherapeutics is a promising biotechnology company at the forefront of TIL therapy. Its recent FDA approval for Amtagvi marks a significant milestone, positioning it to address unmet needs in advanced melanoma. While the company has strong scientific underpinnings and a clear growth strategy, it faces challenges related to manufacturing scalability, market penetration, and competition. Continued success hinges on effective commercial execution and pipeline expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Iovance Biotherapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analyst Reports
- Financial News Outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risks, and investors should conduct their own due diligence before making any investment decisions. Market share data and competitive landscape are estimations and can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iovance Biotherapeutics Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2010-10-15 | Interim CEO, President, General Counsel, Corporate Secretary & Director Dr. Frederick G. Vogt Esq., J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 838 | Website https://www.iovance.com |
Full time employees 838 | Website https://www.iovance.com | ||
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.